Supermolecular inclusion of piroxicam with beta-cyclodextrin: a review of its pharmacological properties in laboratory animals.
Piroxicam-beta-cyclodextrin is a novel NSAID; it is a supermolecular inclusion complex designed to improve the risk:benefit ratio of piroxicam. In animal studies it has been shown to be as effective as piroxicam as an anti-inflammatory and analgesic agent but with a more rapid onset of action and reduced gastropathic effects.
Lister
R E
RE
Phylax Health Care, Beaconsfield, UK.
Acerbi
D
D
Cadel
S
S
D000284:Administration, Oral; D000818:Animals; D003505:Cyclodextrins / Q000493:pharmacokinetics* / Q000627:therapeutic use / Q000633:toxicity; D004064:Digestive System / Q000187:drug effects*; D004338:Drug Combinations; D005260:Female; D007249:Inflammation / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D010146:Pain / Q000188:drug therapy; D010894:Piroxicam / Q000493:pharmacokinetics* / Q000627:therapeutic use / Q000633:toxicity; D047392:beta-Cyclodextrins
D003505:Cyclodextrins; D004338:Drug Combinations; D047392:beta-Cyclodextrins; D010894:Piroxicam; C061072:piroxicam-beta-cyclodextrin